How much can zolbetuximab be reimbursed after it is included in medical insurance?

Zolbetuximab (zolbetuximab) is a monoclonal antibody targeting CLDN18.2 and is widely used to treat a variety of tumors, especially gastric cancer and esophageal cancer. It activates the immune system to attack tumor cells by targeting and inhibiting the unique CLDN18.2 protein on the surface of tumor cells, and has significant therapeutic effects. Although the efficacy of zotuximab has been highly evaluated clinically, it is currently not fully included in the scope of medical insurance reimbursement in China, which puts patients under high financial pressure when using the drug.

In China, the price of zotuximab is affected by many factors, including drug development and production costs, market demand and policy approvals. As zotuximab is an imported innovative drug, its price is relatively high and it has not yet been included in the medical insurance catalog. Therefore, when patients purchase the drug in a hospital or pharmacy, the price varies depending on the region and supply channel. Depending on different market conditions, the price of zotuximab is usually several hundred thousand yuan per year (the specific price may fluctuate depending on the region). For most patients, this means paying for medications out of pocket, and the cost of treatment can bring a significant financial burden.

With the continuous adjustment of national medical insurance policies, especially the gradual increase in attention to anti-cancer drugs, zotuximab may be included in the medical insurance catalog through medical insurance negotiations in the future, thereby achieving certain cost reimbursement. This policy change may significantly reduce the financial burden on patients and enable more patients to benefit from the therapeutic effects of this drug. At the same time, patients can still learn about drug prices from relevant professionals through local hospitals or pharmacies, and make reasonable choices based on their personal financial conditions.

Reference materials:https://www.astellas.com/en/news/29401